文献速递妇科产科

癌症患者的绝经管理

Menopause Management in Patients With Cancer.
PubMed 文献 · Obstet Gynecol · 2026-08-06

本叙述性综述综合随机试验、观察性研究、系统综述及主要学会立场声明,提出基于症状和风险分层的癌症患者绝经管理框架。非激素治疗为各癌种一线选择,阴道雌激素在多数妇科癌症适用,全身激素治疗在激素受体阳性乳腺癌禁忌。

要点

  • 非激素治疗为癌症患者血管舒缩症状一线,支持SSNRIs、加巴喷丁和生活方式干预。
  • 阴道雌激素对绝经泌尿生殖综合征有效,多数妇科癌症适用,乳腺癌幸存者需共同决策。
  • 全身激素治疗在激素受体阳性乳腺癌禁忌,非激素依赖恶性肿瘤或低危妇科癌症可考虑。

核心结论

  • 基于症状和风险分层的管理框架可使妇科医生与肿瘤科协作,为癌症患者提供个体化绝经管理并改善生活质量。

研究设计与样本

  • 叙述性综述,综合随机试验、观察性研究、系统综述和主要学会立场声明的当前证据与指南推荐。

主要发现

  • 癌症治疗患者绝经症状常见且常严重,尤其治疗诱导绝经者,管理需平衡症状缓解与肿瘤安全。
  • 非激素治疗为各癌种一线,强证据支持选择性5-羟色胺和去甲肾上腺素再摄取抑制剂、加巴喷丁及生活方式干预用于血管舒缩症状。
  • 阴道雌激素对绝经泌尿生殖综合征有效,多数妇科癌症适用,部分乳腺癌幸存者共同决策后可考虑。
  • 全身激素治疗在激素受体阳性乳腺癌仍禁忌,非激素依赖恶性肿瘤或低危妇科癌症经仔细选择可考虑。

关键数值与推荐

  • 非激素治疗为各癌种一线治疗。
  • 阴道雌激素在多数妇科癌症适用。
  • 全身激素治疗在激素受体阳性乳腺癌禁忌。

临床怎么用

  • 按症状域和癌症类型及激素敏感性分层评估,与肿瘤科协作制定个体化方案。
  • 关注血栓风险、肝功能、药物相互作用和心血管代谢健康以确保安全。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This Narrative Review provides a practical, symptom-based framework for the management of menopause in patients with cancer, emphasizing risk stratification and collaboration with oncology. Current evidence and guideline recommendations were synthesized from randomized trials, observational studies, systematic reviews, and major society position statements, with findings organized by symptom domain and stratified by cancer type and hormone sensitivity to support clinical decision making. Menopausal symptoms are common and often severe in patients undergoing cancer treatment, particularly in those with treatment-induced menopause, and management requires balancing symptom relief with oncologic safety. Nonhormonal therapies are first-line treatment across cancer types, with strong evidence supporting selective serotonin and norepinephrine reuptake inhibitors, gabapentin, and lifestyle interventions for vasomotor symptoms. Vaginal estrogen is effective for genitourinary syndrome of menopause, is appropriate in most gynecologic cancers, and may be considered in select breast cancer survivors after shared decision making. Systemic hormone therapy remains contraindicated in hormone receptor-positive breast cancer but may be considered in carefully selected patients with non-hormone-dependent malignancies or low-risk gynecologic cancers. Nonhormonal considerations-including thrombotic risk, hepatic function, drug-drug interactions, and cardiometabolic health-are critical to safe management. A symptom-based, risk-stratified approach enables gynecologists to manage menopause in patients with cancer through collaboration with oncology, supporting individualized care and improved quality of life.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Ward KK, Mitchem S, Harichand-Herdt S, et al. Menopause Management in Patients With Cancer. Obstet Gynecol. 2026. PMID: 42561416. doi:10.1097/AOG.0000000000006393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。